Driscoll R. Ugarte is a corporate and securities partner at Duane Morris LLP, resident in the firm's Boca Raton and Miami offices. With nearly 25 years of experience and leadership on transactions exceeding an estimated $15 billion in aggregate value, Mr. Ugarte is a sought-after advisor on mergers and acquisitions, capital markets, securities regulation, and private equity.
Mr. Ugarte advises public and private companies, private equity and venture capital sponsors, institutional investors, family offices, and founders on high-stakes transactions, capital formation, and strategic growth initiatives. Clients rely on him to lead complex domestic and cross-border mergers and acquisitions, sophisticated securities offerings, complex financings, and corporate governance matters, particularly in highly regulated, innovation-driven, and growth-oriented industries. He also advises family officers and institutional investors on tax-efficient structuring, direct investments, and portfolio company governance. Mr. Ugarte counsels clients at every stage of the business lifecycle—from formation and venture financing through growth-stage investment, strategic acquisitions, capital markets transactions, and liquidity events. He also advises multinational corporations and foreign companies on cross-border direct investment, M&A, and U.S. securities law compliance, with particular depth in U.S.–Latin America transactions involving foreign private issuers and multinational operating companies.
Mr. Ugarte is one of a small group of Florida-based corporate and securities lawyers with the depth to handle complex public company representation, from complex cross-border transactions to SEC reporting and corporate governance matters.
Mr. Ugarte serves on the firm’s governing Partners Board, a select body responsible for firmwide strategy, governance, and institutional leadership. He is also co-Team Lead of Duane Morris's Life Sciences and Medical Technologies Industry Group, directing sector strategy, client development, and thought leadership initiatives nationally. His industry focus covers biotechnology, pharmaceutical, and medical technology transactions, including clinical-stage acquisitions, IP-driven deals, and FDA-regulated company financings.
Mr. Ugarte received his J.D. from Georgetown University Law Center and his B.A. cum laude from the University of Florida.
Representative Matters
- Served as lead counsel in the sale of all assets of Scientific Air Management LLC, a hospital equipment supplier.
- Represented a national workers' compensation cost-containment company in its strategic acquisition of a healthcare quality and efficiency analytics firm, including structuring, regulatory, and integration counsel.
- Advised a Taiwan-based medical device manufacturer on its acquisition of a U.S. medical device product line — a cross-border transaction requiring coordination of U.S. securities, FDA regulatory, and international acquisition considerations.
Represented a publicly traded life sciences company in connection with the purchase of assets owned by a Canadian corporation.
Counseled publicly traded financial services company in connection with a reverse triangular merger which resulted in the realization of significant wealth by the majority shareholders.
Represented a publicly traded biopharmaceutical company in connection with the acquisition of a Phase 3 clinical trial-ready drug candidate and all related assets, including the intellectual property and rights to develop and commercialize the drug product.
Represented a publicly traded internet-based weight-loss company in connection with its merger with a provider of interactive private-label nutrition, fitness and wellness programs.
Represented Roundwood Capital, LLC as lead counsel in the $21 million sale of all assets of Rite-Air Mechanical Acquisition Company, LLC.
- Advised the former CEO of Keller Williams Realty in the divestiture of ownership interests in three franchise entities.
- Represented EyeMD EMR Healthcare Systems, Inc. in a significant majority growth equity investment by Performant Capital — a transaction structured as an F-reorganization with a 30% management rollover component and profits interest arrangement, requiring sophisticated tax, governance, and securities structuring.
- Led a team of corporate, tax and real estate attorneys in connection with Lacofin Establishment’s $15 million investment in a newly formed partnership seeking to purchase an island in the Caribbean and build five star resort, single family homes, condos and deep water marina for yachts.
- Advised on the formation, structuring, financing, and investment strategy of four real estate development funds managed by Black Salmon Capital.
- Represented a Florida-based consumer products company in $340 million of aggregate registered public securities offerings, comprising a $150 million debt offering, a $150 million universal shelf registration statement, and a $40 million secondary equity offering.
- Counseled a privately held pharmaceutical technology company in $35 million in private offerings of partnership interests.
- Represented a foreign private issuer in a $43 million public follow-on offering of ordinary shares.
- Advised a publicly traded biopharmaceutical company in registered direct offerings exceeding $20 million involving institutional investors.
- Closed multiple technology-sector transactions—including venture financings, strategic alliances, licensing, development, and supply arrangements—totaling more than $500 million over five years.
- Represented life sciences, medical device, software, and biometric technology companies in financings ranging from $50 million to over $100 million.
Advised a privately-held software development company in connection with several venture capital financings in excess of $50 million.
- Counseled a privately-held orthopedic medical device manufacturer in connection with private financings in excess of $60 million.
Represented a privately-held biometric fingerprint sensor designer and manufacturer in connection with private financings in excess of $80 million.
Represented an electronic health records/patient care management company in connection with a $500,000 investment by an angel group based in Orlando, Florida.
Represented Soligenix, Inc. in connection with its appeal of a delisting determination by Nasdaq Stock Market LLC for failure to comply with Nasdaq Listing Rule 5450(a)(1) (requiring common stock to maintain a minimum closing bid price of $1 for 30 consecutive trading days) and Nasdaq Listing Rule 5550(b)(1) (requiring a minimum of $2.5 million in stockholders’ equity or meet the alternatives of market value of listed securities or net income from continuing operations). Defended a plan of compliance which included the approval of a reverse stock split of Soligenix’s common stock to increase the stock price well above $1 per share and the dividend of super-voting preferred stock that mirrored the actual vote of common stock in order to overcome shareholder apathy and insure approval of the reverse stock split by Soligenix’s stockholders.
Mergers and Acquisitions
Capital Markets, Private Equity and Venture Capital Transactions
SEC Compliance and Corporate Governance
Admissions
- Florida
Experience
- Duane Morris LLP
- Partner (2016-present)
- Associate (2013-2015) Edwards Wildman Palmer LLP (now Troutman Pepper Locke LLP)
- Associate (2005-2013)Broad and Cassel, P.A. (now Nelson Mullins Riley & Scarborough LLP)
- Associate (2003-2005)- U.S. Court of Appeals for the Fifth Circuit
- Judicial Law Clerk (2002-2003)
Education
- Georgetown University Law Center, J.D., 2002
- University of Florida, B.A., cum laude, 1999
Professional Activities
- The Florida Bar
- Hispanic Chamber of Commerce of Palm Beach County
BioFlorida
Association for Corporate Growth
Civic and Charitable Activities
Palm Beach County School Board
- Member, Independent Sales-Surtax Oversight Committee, 2005-2016
Honors and Awards
- Recipient, Lexology / International Law Office Client Choice Award – General Corporate (Florida), 2017 (a peer and client nomination award)
- Recognized as a “Young Attorney on the Rise” by the Daily Business Review
- Named a “Legal Elite Up & Comer” by Florida Trend (2013, 2016)
- Selected to the “Florida Rising Stars” list by Super Lawyers (2010)
Selected Publications
- Author, "SEC Approves New Nasdaq $5 Million Market Value Floor with Immediate Delisting and No Automatic Stay," Duane Morris Alert, July 28, 2026
- Author, "SEC Proposes to Rescind Climate Disclosure Rules – Practical Steps Companies Can Take Now," Duane Morris Alert, June 3, 2026
- Co-author, "Federal Regulatory Response to New World Screwworm and Implications for the Agricultural and Animal Health Industries," Duane Morris Alert, May 28, 2026
- Co-author, "FDA Announces FY2026 Grant Funding for Animal and Veterinary Innovation Centers," Duane Morris Alert, May 27, 2026
- Co-author, "DOJ Proposes Antitrust Settlement with Data Consultant, Requiring Sweeping Changes to Meat Industry Data-Sharing Practices," Duane Morris Alert, May 26, 2026
- Author, "Opinion: To Survive the Downturn, Biotechs Must Return to Basics," BioSpace, April 8, 2026
- Author, "From Hourly to Strategic: How Fixed Fees Are Reshaping Public Company Counsel," Daily Business Review, April 6, 2026
- Author, "Financing and Exit Strategies in Life Sciences: Aligning Capital with Compliance and IP Value," Duane Morris LLP, December 1, 2025, later featured in The Licensing Journal, February 2026
- Co-author, "The Capital Strategy Helping Real Estate Sponsors Expand Funding and Close More Deals," Daily Business Review, July 3, 2025
- Author, "AI-Powered Medtech: What Companies Need to Know About Regulatory and IP Risks," MD+DI Qmed, February 12, 2025
- Co-author, "Beauty and Personal Care Products Post-MoCRA Regulatory Compliance Checklist," Lexis Nexis Practical Guidance, June 2023
- Author, "Changes to Crowdfunding Rules Open the Door for Real Estate Sponsors," Daily Business Review, August 10, 2021
- Co-author, "Proposed Nasdaq Rule Requires Public Disclosure of Board Diversity," Duane Morris Alert, December 9, 2020
Author, "Revamp of Partnership Audit Rules Will Have Broad Effect," Miami Herald, April 30, 2018
Author, "Radical Revamp of Partnership Audit Rules Will Have a Broad Effect," Miami Herald, April 27, 2018
Media Hits
- Quoted in "SEC Climate Disclosure Rules May Be History, But Some Risk Remains," Corporate Counsel, June 14, 2026
- Quoted in "A Change in SEC Rules Means Food and Booze Brands Are Raising Millions Through Crowdfunding - and Scooping up Customer Data Too," Business Insider, October 14, 2021
- Quoted in "Tips on Buy-Sell Agreements," South Florida Business and Wealth, April 2019
- Quoted in "Duane Morris Partner Closes Stock Sale for Biopharmaceutical Company," Daily Business Review, December 12, 2017
Selected Speaking Engagements
- Presenter, “2025 Legal Hot Issues: Navigating the New Administration and Emerging Corporate Compliance Priorities” (including Corporate Transparency Act and anticipated regulatory shifts), Global Ventures Lunch and Learn, Research Park at Florida Atlantic University, December 19, 2024
Speaker, "Wealth Preservation: Are Your Assets Properly Protected From Creditors?" Duane Morris Doing Business in South Florida Roundtable Series, August 14, 2019
Moderator, "The Role of Private Equity and Venture Capital in Seeding the Future: Challenge and Opportunity in Early Stage Impact Investing,” Opal Group's Impact Investment Forum, West Palm Beach, Florida, April 1-3, 2019
Panelist, "Meet the Angels," FAU Tech Runway, Boca Raton, March 29, 2019
Panelist, "Business Succession Planning," The Owner's Journey, FAU Tech Runway, February 2019




